Vident Investment Advisory’s Meridian Bioscience Inc VIVO Stock Holding History

Vident Investment Advisory’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-70,694	Closed	-$2.23M	–	1376
2022 Q3	$2.23M	Buy	+70,694	New	+$2.29M	0.07%	308
2018 Q4	–	Sell	-38,229	Closed	-$570K	–	957
2018 Q3	$570K	Buy	38,229 +10,929	+40%	+$169K	0.02%	645
2018 Q2	$434K	Buy	27,300 +5,680	+26%	+$84.7K	0.02%	705
2018 Q1	$318K	Buy	21,620 +6,092	+39%	+$90.2K	0.01%	772
2017 Q4	$217K	Buy	+15,528	New	+$227K	0.01%	754
2017 Q3	–	Sell	-10,771	Closed	-$170K	–	785
2017 Q2	$170K	Buy	+10,771	New	+$155K	0.01%	430
2015 Q4	–	Sell	-37,525	Closed	-$642K	–	903
2015 Q3	$642K	Buy	37,525 +2,311	+7%	+$42.2K	0.09%	384
2015 Q2	$656K	Buy	35,214 +1,789	+5%	+$33.2K	0.09%	327
2015 Q1	$638K	Buy	33,425 +10,786	+48%	+$199K	0.13%	250
2014 Q4	$373K	Buy	+22,639	New	+$388K	0.13%	378

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vident Investment Advisory's VIVO Position: Q4 2022 in Review

Vident Investment Advisory sold out of Meridian Bioscience Inc (VIVO) in Q4 2022, closing a stake of 70,694 shares — an estimated $2.23M sold.

Vident Investment Advisory first reported a position in VIVO in Q4 2014 and held it in 10 quarters. The position peaked at $2.23M in Q3 2022. 218 funds tracked by Wall St. Rank hold VIVO as of Q4 2022.

Vident Investment Advisory reported no remaining Meridian Bioscience Inc position as of Q4 2022 after selling out during the quarter.
Vident Investment Advisory sold 70,694 Meridian Bioscience Inc shares in Q4 2022, an estimated $2.23M.
Vident Investment Advisory first reported a position in Meridian Bioscience Inc in Q4 2014 and held it in 10 quarters.
Vident Investment Advisory's Meridian Bioscience Inc position peaked at $2.23M in Q3 2022.
218 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2022.

Based on Vident Investment Advisory's 13F filing for Q4 2022, filed 14 Feb 2023.